Liver Disease Diagnosis and Management

Biomarkers and Assessment

• GGT is a sensitive marker (73% sensitivity) for chronic alcohol misuse, often used in combination with other markers like CDT (69% sensitivity, 92% specificity) for alcohol consumption detection, and may be used as part of fibrosis assessment tools like FibroTest 1
• Documenting excess alcohol consumption (>30 g/day) is important for assessing alcohol consumption, and GGT has high sensitivity but limited specificity for liver disease 1
• Other markers for detecting alcohol consumption include carbohydrate deficient transferrin (CDT) and AST levels, with the AST/ALT ratio suggesting alcoholic liver disease (ratio >2 indicating possible, ratio >3 indicating high probability) according to the American Association for the Study of Liver Diseases 2
• The R value [(ALT/ULN)/(ALP/ULN)] can be used to determine the pattern of liver injury, with a hepatocellular pattern indicated by R ≥5, a cholestatic pattern by R ≤2, and a mixed pattern by R >2 and <5, as recommended by the American Association for the Study of Liver Diseases 3

Imaging and Diagnostic Criteria

• The following imaging modalities are recommended for specific indications:

4, 5, 6, 7, 8

• Ultrasound provides unique and complementary information to CT scanning, particularly for hepatobiliary assessment, with benefits including no radiation exposure, more accessibility, and lower expense than CT or MRI, as stated by the American College of Radiology 9
• The following diagnostic criteria can be used to evaluate liver disease:

10

Management and Treatment

• Abstinence from alcohol is the primary intervention for alcoholic liver disease, and nutritional support is also recommended, according to the American College of Gastroenterology 11
• Disease-specific treatments, such as ursodeoxycholic acid for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), may be considered for patients with liver origin ALP elevation, as recommended by the European Association for the Study of the Liver 5
• Patients on medications with potential hepatotoxicity should be monitored with liver tests before each treatment cycle or at least monthly, and continuation of monitoring for at least five half-lives after treatment cessation, as recommended by the Food and Drug Administration 12

Monitoring and Follow-up

• Repeat liver enzymes (including GGT) every 3-6 months, and follow-up imaging based on clinical course, are recommended for monitoring, according to the American Gastroenterological Association 13
• Referral to a specialist is considered if GGT remains elevated >3× upper limit of normal despite lifestyle modifications, or if there is evidence of advanced fibrosis, as recommended by the American Association for the Study of Liver Diseases 13
• Patients with chronic hepatitis delta (CHD) and advanced fibrosis or cirrhosis should undergo HCC surveillance with abdominal ultrasound every 6 months, regardless of anti-HDV therapy, as recommended by the American Association for the Study of Liver Diseases 14

Screening and Risk Stratification

• The World Health Organization recommends using validated screening tools, such as the AUDIT questionnaire, to identify patients with harmful drinking patterns 2
• The National Institute for Health and Care Excellence suggests calculating average daily alcohol intake using a specific formula, and considering risk stratification with clinical assessment and Fibroscan/ARFI elastography for patients with harmful drinking patterns 11, 15